EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)

A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma

Wanyue Zhao iD, Ling Li, Xiaorui Fu, Yu Chang, Zhenchang Sun, Linan Zhu, Xin Li, Xinhua Wang, Jiaqin Yan, Sisi Jia, Shanshan Ma iD, Mengke Fan und 7 weitere

Cancer · 2026

DOI: 10.1002/cncr.70247 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2026. Verfasst von Wanyue Zhao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Agammaglobulinaemia Tyrosine Kinase, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Outstanding Youth Item of Henan Health-Related Technological and Innovative Talents Project, Clinical Medical Scientist Training Program under the 'Three 100s' Initiative of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary central nervous system lymphoma (PCNSL) is an aggressive, immune‐privileged, large B‐cell lymphoma with limited frontline treatment options.

Methods

This study was an open‐label, single‐arm, phase 1/2 trial evaluating orelabrutinib combined with an anti–programmed cell death protein‐1 (PD‐1) antibody and a non‐methotrexate chemotherapeutic agent (fotemustine) in patients with newly diagnosed PCNSL (ClinicalTrials.gov identifier NCT04831658). Orelabrutinib was tested at three dose levels (100, 150, and 200 mg), and the recommended phase 2 dose was determined as 150 mg. In phase 2, patients received orelabrutinib 150 mg orally once daily, a PD‐1 inhibitor 200 mg intravenously on day 1, and fotemustine 100 mg/m 2 intravenously on day 2 every 21 days for six cycles. The primary endpoint was the objective response rate.

Results

From February 2021 to October 2023, 31 patients (median age, 62 years; age range, 37–70 years) were treated, and 27 were evaluable for efficacy. The objective response rate was 85.2% (complete response, 66.7%; partial response, 18.5%). The median progression‐free survival was 9.4 months (95% confidence interval, 5.4–13.4 months), and the median overall survival was 22.8 months (95% confidence interval, 1.1–44.5 months). The 1‐year and 2‐year overall survival rates were 68.0% and 48.0%, respectively. The most common grade 3/4 adverse events were thrombocytopenia (45.2%), pulmonary infection (38.7%), and leukopenia (25.8%).

Conclusions

Orelabrutinib combined with PD‐1 blockade and fotemustine demonstrated high antitumor activity with manageable toxicity, supporting its potential as a frontline regimen for PCNSL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAgammaglobulinaemia Tyrosine KinaseProgrammed Cell Death 1 ReceptorLymphomaHumansMaleFemaleMiddle AgedAgedAdultNitrosourea CompoundsOrganophosphorus CompoundsPyrazinesMethotrexateProtein Kinase Inhibitors

Stichwörter der Autor:innen

Bruton's tyrosine kinase inhibitorfotemustinemethotrexate‐free regimenprimary central nervous system lymphomaprogrammed cell death protein‐1 inhibitor

Substanzen

Agammaglobulinaemia Tyrosine KinaseProgrammed Cell Death 1 ReceptorNitrosourea CompoundsOrganophosphorus CompoundsPDCD1 protein, humanPyrazinesBTK protein, humanMethotrexateProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Oncology, Xinxiang Central Hospital, Xinxiang, China.
  • Henan Academy of Innovations in Medical Science, Zhengzhou, China.

ORCID-Profile: Wanyue Zhao, Shanshan Ma, Honghan Qiao, Qingjiang Chen, Mingzhi Zhang, Xudong Zhang

Förderung

  • Outstanding Youth Item of Henan Health-Related Technological and Innovative Talents Project
  • Clinical Medical Scientist Training Program under the 'Three 100s' Initiative of Henan Province

Zitieren

APA

Zhao, W., Li, L., Fu, X., Chang, Y., Sun, Z., Zhu, L., Li, X., Wang, X., Yan, J., Jia, S., Ma, S., Fan, M., Qian, S., Zhang, Y., Yang, Q., Qiao, H., Chen, Q., Zhang, M., & Zhang, X. (2026). A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma. Cancer. https://doi.org/10.1002/cncr.70247

Vancouver

Zhao W, Li L, Fu X, Chang Y, Sun Z, Zhu L, et al. A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma. Cancer. 2026. doi:10.1002/cncr.70247

BibTeX
@article{Zhao2026,
  author = {Zhao, Wanyue and Li, Ling and Fu, Xiaorui and Chang, Yu and Sun, Zhenchang and Zhu, Linan and Li, Xin and Wang, Xinhua and Yan, Jiaqin and Jia, Sisi and Ma, Shanshan and Fan, Mengke and Qian, Siyu and Zhang, Yue and Yang, Qing and Qiao, Honghan and Chen, Qingjiang and Zhang, Mingzhi and Zhang, Xudong},
  title = {A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70247}
}
Kostenlos starten →